RELA and hepatocellular carcinoma: Our study demonstrated that treatment of tumor-bearing mouse models of hepatocellular carcinoma with different TKIs such as apatinib, lenvatinib, and regorafenib resulted in increased activation of RelA signaling in glomerular endothelial cells and podocytes.